Insider Transactions in Q2 2021 at Lumos Pharma, Inc. (LUMO)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2021
|
Chad Allen Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+25.43%
|
-
|
|
May 20
2021
|
Kevin M. Lalande Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+25.43%
|
-
|
|
May 20
2021
|
Joseph S Mc Cracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+25.43%
|
-
|
|
May 20
2021
|
Thomas A. Raffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+4.26%
|
-
|
|
May 20
2021
|
An Van Es Johansson Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+25.02%
|
-
|
|
May 20
2021
|
Lota S. Zoth Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+14.37%
|
-
|
|
Apr 01
2021
|
Richard J Hawkins Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,522
-0.2%
|
$18,264
$12.25 P/Share
|
|
Apr 01
2021
|
Carl W. Langren Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
683
-5.61%
|
$8,196
$12.25 P/Share
|
|
Apr 01
2021
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-4.8%
|
$3,288
$12.25 P/Share
|
|
Apr 01
2021
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,036
-7.26%
|
$12,432
$12.25 P/Share
|
|
Apr 01
2021
|
Bradley J Powers General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-6.31%
|
$4,104
$12.25 P/Share
|